ABSTRACT
INTRODUCTION
In many cultures, Cannabis sativa (cannabis) has been a traditionally valuable crop, heralded for its versatility as a fibre, food source, recreational drug and medicine. 1 It's use in ethnopharmacology is well established for treatment of pain and inflammation 2 and it is now the target of pharmacognosy studies to explore the potential of application within conventional medicine for treatment of ailments including cancer, pain, loss of appetite, nausea, vomiting, anxiety and drug resistant epilepsy. 3, 4 Traditionally the cannabis plant is smoked or consumed orally as a tea or in foods 5 and smoking remains the most popular intake method today. 6 Although medicinal efficacy of cannabis is largely attributed to the presence of cannabinoids, in particular the psychoactive cannabinoid delta-9-tetrathydrocannabinol (THC), cannabis plant material contains many other bioactive compounds which may also be contributing to its therapeutic effect. 2, 7, 8 Plant extracts containing multiple bioactive compounds have been shown to exhibit enhanced medicinal efficacy than the sum of their individual components, a phenomenon known as pharmacodynamic synergy or the entourage effect. 9, 10 Accordingly, cannabinoid and non-cannabinoid phytochemicals may be individually or synergistically contributing to the medicinal efficacy of cannabis. Understanding the pharmacokinetics of medicinal compounds is critical for establishing safe and effective administration practises. While in-vivo approaches may be preferred, in-silico predictive models have proven to be powerful, cost-effective tools, for fast and efficient pharmacokinetic approximations to guide usage and designing future clinical studies.
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The in-silico phytochemical absorption prediction (PCAP) model presented in Selby-Pham et al. 12 has been applied to predict phytochemical pharmacokinetics of plant extracts to guide recommended intake times for maximal health benefits. 13 This optimisation utilises the concept of 'biomatching' , wherein maximal medicinal efficacy is achieved by aligning plasma concentrations of stress-mediating compounds with periods of associated stressors. 12, 14 For example, extracts from Hyptis sp. and Hypericum perforatum were recommended to be ingested two hours prior to meals to achieve maximal stress mediation from absorbed antioxidant phytochemicals by biomatching the time of maximal plasma concentration (T max ) with the period of postprandial oxidative stress. 15, 16 Accordingly, the capacity to predict T max has allowed determination of optimal intake times to biomatch chemical activities with the timings of their maximal benefit.
Elimination half-life (T ½ ) describes time for plasma drug concentrations (PDC) to halve following intake and thereby guides determination of loading dosages, dosing intervals and bolus dose. 17, 18 Accordingly, the T ½ of medicinal compounds must be accounted for when determining dosage regimens to ensure that PDC remains within the effective range and does not reach toxic or subtherapeutic levels. 19 Whilst the PCAP model is available for in-silico pharmacokinetic predictions following ingestion, no equivalent model for predicting inhalation pharmacokinetics is well established. The PCAP model targets intake time to maximise health benefits of ingested compounds by biomatching T max with peak time of stressors. By contrast, health benefits of inhaled compounds are maximised by targeting dosing intervals to maintain effective PDC range based on T ½ , as T max for inhaled compounds is near instant and provides little room for optimisation. 20 Herein the in-silico inhalation absorption prediction (IAP) model is presented for predicting the pharmacokinetics (T max and T ½ ) of phytochemicals and other compounds following inhalation. The model is used to develop functional fingerprints for bioactive phytochemicals, which can be used to achieve biomatching of their maximal activity with optimal effect time. 
MATERIALS AND METHODS

Inhalation Absorption Prediction (IAP) model development
A training set of in-vivo pharmacokinetic data from 14 inhaled compounds (isolated compounds or compounds present within their native plant-material matrix) was used to develop regression equations for T max and T ½ . In-vivo pharmacokinetic data was sourced from the following publications: Cass et al., 21 Cone, 22 Drollmann et al., 23 Jāger et al., 24 Kirby et al., 25 Lecaillon et al., 26 Marsot et al., 27 Neale et al., 28 Richards et al., 29 Rix et al., 30 Schneider et al., 31 Skoner 32 Spyker et al., 33 Thorsson et al., 34 Usmani et al., 35 and Vaisman et al. 36 Physicochemical data for training compounds was collected from the online property calculation toolkit, Molinspiration (http://www.molinspiration.com). Physicochemical measures utilised included molecular weight (MW), lipophilicity descriptor (log P), topological polar surface area (TPSA), number of freely rotatable bonds (nrot) and molecular volume (Vol). The relationship between the physico chemical data and the published T max and T ½ was explored by statistical analyses to identify physicochemical properties with predictive power for each pharmacokinetic measure. Linear regressions were performed in Minitab 18 statistical software (Minitab Inc., State College, Pennsylvania, USA). The equations predicting T max and T ½ from physicochemical properties and their application to produce functional fingerprints for plasma concentration following inhalation, are herein referred to as the inhalation absorption prediction (IAP) model.
Production of functional fingerprints
Functional fingerprints were generated as per the IAP model using predicted T max and T ½ for test compounds (equations 1 and 2). In short, equations 1 and 2 were used to calculate 7 key pharmacokinetic time points (T 1 =T 0 , T 2 =T max , T 3 =T ½ , T 4 =2*T ½ , T 5 =3*T ½ , T 6 =4*T ½ and T 7 =5*T ½ ), with the plasma concentration at T 1 assigned a value of 0 and T 2 (T max ) assigned the maximal plasma concentration (C max ) if known, else a relative value of 100%. Additionally, T 3 (T ½ ) through T 7 , representing 5 half-lives, were assigned plasma concentrations half that of their previous time point. These time points were connected via 6 regression equations (y=m 1 x+c 1 , y=m 2 x+c 2 , y=m 3 x+c 3 , y=m 4 x+c 4 , y=m 5 x+c 5 and y=m 6 x+c 6 ) to produce a functional fingerprint describing predicted plasma concentration over time following inhalation at T 1 .
Biomatching of cannabis phytochemicals
The IAP model was applied to data from Mediavilla and Steinemann 37 and Greenwald and Stitzer 38 to produce functional fingerprints for three cannabis phytochemicals; THC, myrcene and caryophyllene. The functional fingerprints were compared to data from Greenwald and Stitzer 38 to explore temporal biomatching between plasma concentrations of the three phytochemicals and observed physiological effects, following inhalation of cannabis treatment or placebo cigarettes. In short, the study by Greenwald and Stitzer 38 involved patients smoking 4 bouts of 3 cigarettes weighing between 750 to 990 mg followed by testing for a range of physiological and psychological effects. Cannabis THC concentrations were determined from Greenwald and Stitzer 38 whilst myrcene and caryophyllene concentrations were based on the medicinal strain "Swiss mix" and fibre strain "Fedora" from Mediavilla and Steinemann, 37 as representative profiles of the treatment and placebo cigarettes, respectively. The treatment cigarettes (49.3% myrcene, 19.5% caryophyllene and 3% THC) were inhaled in combination with placebo cigarettes (29.4% myrcene, 37.5% caryophyllene and 0% THC) in Greenwald and Stitzer 38 to achieve overall phytochemical inhalation described in Table 1 . . Preliminary model development explored the relationships between individual physicochemical parameters and the pharmacokinetic measures T max and T ½ . Individual physicochemical parameters had poor predictive power (Supplemental Table S3 ), with visualisation of either T max or T ½ with singular physicochemical measures (Figure 1) suggesting the possibility for non-linear relationships or the necessity for multiple measures to achieve predictive power. This is consistent with previous pharmacokinetic studies, such as the PCAP model, 12 which have shown that following consumption, individual measures had poor predictive power while a combination of measures could be used to achieve a model with greater predictive power. Pearson's correlation coefficients (Supplement Table S2 ) were used to assess the power of physicochemical properties to predict pharmacokinetic properties based on the categorisation of strength of correlation as; r < 0.3 negligible, 0.3 < r < 0.5 low, 0.5 < r < 0.7 moderate, 0.7 < r < 0.9 high and r > 0.9 very high. 39 T max showed negligible correlation with nrot (r = 0.171), low correlation with log P (r = 0.343), Vol (r = 0.403) and MW (r = 0.412) and a moderate correlation with TPSA (r = 0.576). By contrast, T ½ showed a negligible correlation with TPSA (r = 0.010), low correlation with nrot (r = 0.329) and log P (r = 0.349) and a moderate correlation with Vol (r = 0.506) and MW (r = 0.528). These results were dissimilar to Selby-Pham et al. 12 which observed moderate correlation for molecular weight and high correlation for log P and TPSA to T max following ingestion. Accordingly, physicochemical properties impacting inhalation pharmacokinetics were deemed to be different from those impacting ingestion pharmacokinetics. Physicochemical properties that showed low or moderate correlation with pharmacokinetic measures were further explored to determine if a combination of properties or non-linear regression could achieve improved predictive power ( Figure 1A-C, E-G) . The T max regression model (Equation 1) had an r 2 = 0.84 ( Figure 1D ) and utilised the predictors: TPSA (P = 0.007), Vol (P = 0.003), TPSA*Vol (P = 0.003), MW*Vol (P = 0.005) and TPSA*MW*Vol (P = 0.003). Similarly, the T ½ regression model (Equation 2) had an r 2 = 0.87 ( Figure 1H ) and utilised the predictors: MW (P = 0.011), Vol (P = 0.015), MW 2 (P = 0.016), Vol 2 (P = 0.006), nrot 2 (P = 0.028), MW*Vol (P = 0.008) and MW*nrot (P = 0.032). 
Application of the IAP model to predict phytochemical decay in plasma
The IAP model was used to create functional fingerprints predicting compound plasma levels following inhalation (Figure 2A ). The functional fingerprints were constructed according to five iterations of the T ½ function, when plasma levels are said to have reached steady state and 97% of the compound has been cleared from the body. 17 The capacity to predict when a compound achieves steady state is particularly useful for guiding dosage intervals to maintain a threshold PDC for drug efficacy and mitigate the risk of toxicity. 19 The IAP model was applied to two cannabinoids THC and cannabidiol (CBD), to compare predicted T max against in-vivo data. The T max for THC and CBD were observed as 0.05 h and 0.11 h, respectively, 40, 41 while the predicted T max were 0.02 h and 0.03 h, respectively. Considering that T max predictions within 1.5 h of observation are considered to be accurate predictions, 15 these differences (average 4 min) were considered to be within the acceptable range of pharmacokinetic predictions. The IAP model was further applied to THC, CBD and the metabolites THC-COOH and 11-OH-THC to compare predicted T ½ ( Figure 2C ) against in-vivo data ( Figure 2B ) presented in Nadulski et al. 42 Considering that the compounds in Nadulski et al. 42 were ingested (not inhaled), only comparisons between their elimination half-lives (T ½ ) were made, as T ½ is only dependent on the compound not its method of intake. For example, the T ½ for nicotine, taken as either a cigarette, intravenous injection, sucking lozenge, or chewing gum was shown to be in the narrow range of 2.0-2.5 h. [43] [44] [45] The T ½ observed in Nadulski et al. 42 for THC-COOH, 11-OH-THC, THC and CBD were 3.93 h, 2.88 h, 1.59 h and 1.56 h, respectively, while the predicted T ½ were 2.98 h, 2.08 h, 1.63 h and 1.61 h, respectively. The resulting difference between observed and predicted T ½ across the four compounds was on average 27.7 min. The IAP model was therefore shown to accurately predict both T max and T ½ and thereby produce functional fingerprints which may be used in pharmacognosy to explore the phytochemistry underpinning the efficacy of medicinal plants.
Case study: Biomatching cannabis phytochemicals to their medicinal effects
The IAP model was applied to explore biomatching between predicted cannabis phytochemical PDC and physiological effects following the smoking of cannabis reported in Greenwald and Stitzer. 38 Predicted plasma THC concentrations aligned closely with reported measures for increases in good mood ( Figure 3A) . The THC-induced mood-elevating effect following cannabis inhalation is well established and is thought to confer antidepressant-like effects by interacting with the endocannabinoid system. 46, 47 Additionally, the predicted lag in plasma THC concentrations (due to the initial inhalation of placebo cigarettes) matched to the observed lag in mood elevation of 0.875 h ( Figure 3A ). This consistency supports the interpretation of THC as the phytochemical causing mood elevation following cannabis inhalation and highlights the precision and potential applications of the IAP model. The IAP model was used to explore biomatching between observed antinociceptive effects reported in Greenwald and Stitzer 38 with the combined concentrations of myrcene and caryophyllene ( Figure 3B) , which have previously shown analgesic and antinociceptive effects in mice. 8, 48, 49 Predicted plasma levels of myrcene and caryophyllene generally aligned with antinociceptive effects, including alignment of the gradual decrease in antinociceptive effects (0.25-0.85 h, Figure 2B ) with the predicted decline in myrcene and caryophyllene plasma concentrations. Whilst Greenwald and Stitzer 38 attribute this observed antinociceptive effect to THC, the onset of antinociception did not align with the inhalation of THC-containing "treatment" cigarettes, but did align with myrcene and caryophyllene which were present in both "treatment" and "placebo" cigarettes. Accordingly, while THC may be contributing via the entourage effect, 8 it appears to be playing a lesser role than myrcene and caryophyllene in antinociception. These results support the ability of the IAP model to accurately predict compound clearance rates after inhalation via predicted T ½ and highlight how the IAP model may be used to explore phytochemical modes of action by biomatching during pharmacognosy analyses of medicinal plants.
CONCLUSION
The present study describes the inhalation absorption prediction (IAP) model, an in-silico pharmacokinetic model for predicting plasma drug concentration (PDC) following inhalation. The model calculates compound accumulation rate via T max and compound clearance rate via T ½ , to achieve a functional fingerprint which accurately predicts temporal changes of PDC. The model demonstrates biomatching between medicinal effects; good mood and antinociception, with predicted plasma levels of THC and combined levels of myrcene and caryophyllene, respectively. The alignment between timings of the observed medicinal effects and increased plasma levels supports the application of the IAP model to explore the modes of action of medicinal phytochemicals and to guide drug loading dosages and frequency to achieve and maintain therapeutic PDC. The IAP model is therefore a novel and powerful tool for guiding future clinical trials of inhaled medicinal compounds. 
